Kuva Labs Announces $1.2 Billion Acquisition of Lisata Therapeutics in Strategic Biotech Expansion

Kuva Labs has entered into a definitive agreement to acquire Lisata Therapeutics for $1.2 billion in an all-cash transaction, the companies announced on March 9, 2026. The acquisition is structured as a merger with Lisata becoming a wholly owned subsidiary of Kuva Labs, with shareholders of Lisata receiving $18.50 per share in cash. The deal is subject to customary closing conditions and regulatory approvals, with an anticipated completion by mid-2026. The acquisition reflects Kuva Labs’ strategic focus on expanding its portfolio of gene therapies targeting rare and genetic disorders. Lisata Therapeutics, headquartered in San Diego, California, is advancing a clinical-stage platform focused on AAV-mediated gene editing, including programs in hemophilia B and Leber congenital amaurosis. The integration of Lisata’s pipeline is expected to accelerate Kuva’s development timeline for next-generation therapies and bolster its intellectual property position. Upon closing, the combined entity will have a pipeline of 14 clinical and preclinical programs, with three candidates in Phase 2 trials and one in Phase 1. The transaction is expected to be accretive to Kuva Labs’ non-GAAP earnings per share by fiscal year 2027. The deal follows a period of increased M&A activity in the biotech space, with investors viewing strategic acquisitions as a key driver of growth amid persistent R&D uncertainty. The acquisition is likely to impact investor sentiment across the biotech sector, with shares of LSTT surging 28% in premarket trading on the news and KUVA rising 6%. Market analysts indicate that the deal may encourage further consolidation among mid-cap biotech firms seeking scale and access to advanced platforms.